NLE Paediatric Nursing — Paediatric Hematologic, Oncologic & Genetic DisordersStudy Notes

Leukemia is the leading cause of cancer death in children, accounting for approximately 28–30% of all childhood malignancies. Acute lymphoblastic leukemia (ALL) is the most common type, with a peak incidence between 2–5 years of age. The good news is that modern chemotherapy has dramatically improved the 5-year survival rate to 80–90% in resource-rich settings; however, outcomes remain challenging in settings with limited access to chemotherapy and supportive care, a reality for many paediatric patients in the Philippines.

Pathophysiology: Leukemia arises from uncontrolled proliferation of immature white blood cells (blasts) that crowd out normal blood cell production in the bone marrow. This leads to pancytopenia—a reduction in all three cell lines—with three major consequences:

1. Anemia (low red blood cells): Results in pallor, fatigue, dyspnea, and poor exercise tolerance. Children may appear pale and listless.
2. Neutropenia (low functional white blood cells): The most serious consequence. Neutropenia, defined as an absolute neutrophil count (ANC) < 500 cells/μL, dramatically increases infection risk. In leukaemic children, normal immune function is further compromised by chemotherapy. Fever in a neutropenic child is a medical emergency and a leading cause of death in childhood leukemia.
3. Thrombocytopenia (low platelets): Increases bleeding risk, manifesting as petechiae (tiny red/purple pinpoint spots that don't blanch), purpura (larger bruises), and spontaneous bleeding.

Clinical Presentation: Children typically present with fever, bone/joint pain (often mistaken for "growing pains"), fatigue, pallor, and easy bruising. On physical examination, hepatosplenomegaly (enlarged liver and spleen) and lymphadenopathy (enlarged lymph nodes) are common. Some children present acutely ill (fever, bleeding, infection), while others have a more insidious onset over weeks to months.

Diagnosis is confirmed by bone marrow aspiration and biopsy, which shows >25% blasts. The complete blood count (CBC) reveals anaemia, thrombocytopenia, and often leukocytosis (high WBC) with circulating blasts visible on the differential.

PRIORITY NURSING DIAGNOSIS (using Maslow's hierarchy of needs):

• Immediate physiological needs (Level 1): Risk for infection (related to neutropenia secondary to leukemia and chemotherapy) and Risk for injury/bleeding (related to thrombocytopenia).
• Secondary concerns: Imbalanced nutrition less than body requirements, Nausea, Alopecia, and Anxiety/coping difficulties for the child and family.

Critical Nursing Interventions: Neutropenic Precautions

When a child's ANC drops below 500 cells/μL (usually during chemotherapy), strict neutropenic precautions are essential. These are non-negotiable safety measures:

• Hand hygiene: Meticulous, frequent handwashing is the cornerstone. All visitors, staff, and family members must wash hands thoroughly before entering the room and before any direct contact.
• Room isolation: A private room is ideal; high-efficiency particulate air (HEPA) filtration is used in some tertiary centres. A single room prevents cross-contamination from other patients' organisms.
• No fresh flowers, plants, or potted plants: These harbor Pseudomonas and fungal spores that can cause serious infections in immunocompromised children.
• Dietary restrictions: No fresh fruits or vegetables with peels, no raw or undercooked meat/eggs, no unpasteurised dairy products. The gut harbours normal flora that can become pathogenic in severe neutropenia. Serve cooked, warm foods.
• No crowds or visits from sick people: Limit visitors; exclude anyone with fever, cough, or known illness. Avoid public spaces and crowds.
• Strict aseptic technique: All IV lines, catheters, and procedures must follow rigorous aseptic technique to prevent introduced infection.
• Avoid invasive procedures: No rectal temperatures (risk of perforation and infection), no suppositories, no rectal examinations, no IM injections (risk of local infection). Use axillary or oral temperatures and SC injections if needed.
• Temperature monitoring: Check temperature at least every 4 hours. A fever (≥38.5°C oral or ≥38°C axillary) in a neutropenic child is a medical emergency. Do not delay: obtain blood cultures, start broad-spectrum antibiotics, and notify the physician immediately. This is a common high-yield NLE point.
• Mouth care: Frequent saline gargles and soft toothbrush to prevent mucositis-related infection.
• Avoid live vaccines: Contraindicated during immunosuppressive chemotherapy; defer until immune recovery.

Bleeding Precautions

When platelets fall below 20,000/μL, spontaneous bleeding becomes likely. Implement:

• Soft toothbrush; avoid flossing.
• No contact sports or activities with high fall risk.
• No aspirin or NSAIDs (impair platelet function); use acetaminophen.
• Avoid IM injections; use IV or SC routes.
• Monitor for signs of intracranial bleed (headache, vomiting, altered mental status, seizures)—a life-threatening complication.
• Use pressure garments or sandbags if bleeding into joints (hemarthrosis).

Chemotherapy Management

Most children with leukemia receive multi-agent chemotherapy protocols (e.g., vincristine, daunorubicin, asparaginase, cyclophosphamide). The nurse must:

• Follow chemotherapy safety protocols (RA 9173 emphasises the nurse's duty to administer medications safely and to prevent medication errors).
• Administer antiemetics BEFORE chemotherapy: Ondansetron or granisetron given 30 minutes before treatment reduces nausea/vomiting significantly.

• Monitor for and manage predictable side effects:

  • Nausea/vomiting: Offer small, frequent, bland meals; avoid strong smells and heavy foods; administer antiemetics on schedule.
  • Mucositis (mouth sores): Frequent mouth rinses with normal saline, avoid commercial mouthwash (alcohol is drying and irritating), assess for oral candidiasis (white patches), use soft bland non-acidic foods.
  • Alopecia (hair loss): Reassure the family that hair regrows 3–6 months after therapy ends. Offer age-appropriate explanations (e.g., "The medicine is strong and affects fast-growing cells, like hair"), allow the child to choose a hat or wig, and validate the psychological impact.
  • Constipation: Some agents (especially vincristine) cause peripheral neuropathy affecting gut motility. Ensure adequate hydration, fibre, and use of stool softeners or laxatives as prescribed.
  • Myelosuppression: Manage as outlined above.
• Monitor vital signs, weight, and intake/output closely: Ensure adequate hydration and nutrition during treatment.
• Provide family education and psychosocial support: A childhood cancer diagnosis is a crisis. The nurse, as a key member of the multidisciplinary team, offers emotional support, clarifies treatment goals, and connects families to resources (social work, psychology, support groups).

Hemophilia is a lifelong inherited bleeding disorder caused by deficiency of a clotting factor. It is the most common X-linked recessive bleeding disorder, meaning it primarily affects males, and affected males' mothers are carriers. Females with hemophilia are rare (usually requiring an affected father and carrier mother).

Types:

• Hemophilia A (Factor VIII deficiency): Accounts for approximately 80–85% of hemophilia cases. Factor VIII is a critical cofactor in the intrinsic coagulation pathway.
• Hemophilia B (Factor IX deficiency, "Christmas disease"): Accounts for 15–20% of cases.

Pathophysiology and Genetics:

The genes for Factors VIII and IX are located on the X chromosome. Males (XY) with a mutated gene have hemophilia; females (XX) with one mutated gene are carriers (usually asymptomatic due to X-inactivation, but some may have mild symptoms). The inheritance pattern:

• Affected male × normal female: All daughters are carriers; all sons are normal.
• Carrier female × normal male: 50% of sons have hemophilia; 50% of daughters are carriers.
• Affected male × carrier female: 50% of daughters have hemophilia; 50% of sons have hemophilia; 50% of sons are normal.

Clinical Presentation:

The hallmark is prolonged bleeding with normal platelet count and bleeding time but prolonged activated partial thromboplastin time (aPTT). The severity depends on the factor level:

• Severe (<1% factor activity): Spontaneous bleeding into joints (hemarthrosis), muscles, and internal organs. Even minor trauma can trigger serious bleeds.
• Moderate (1–5% factor activity): Bleeding with trauma; some spontaneous episodes.
• Mild (>5% factor activity): Bleeding with significant trauma or after surgery; may remain undiagnosed until an injury or procedure.

Common Bleeding Manifestations:

1. Hemarthrosis (bleeding into joints): The most frequent and disabling complication, especially affecting knees, elbows, ankles, and hips. Presents as acute joint pain, swelling, warmth, and decreased range of motion. Repeated bleeds lead to chronic synovitis and joint destruction (arthropathy).
2. Easy bruising and hematomas: Bruises appear large and disproportionate to the injury; may develop days after trauma.
3. Muscle hematomas: Can compress nerves and blood vessels; intramuscular injections are particularly dangerous.
4. Mucosal bleeding: Nosebleeds, gum bleeding, and GI bleeding.
5. Intracranial bleeding: A rare but life-threatening complication; head injury must always be taken seriously and investigated.

Diagnosis:

• CBC: Normal hemoglobin and platelet count.
• Bleeding time: Normal (tests platelet function, not clotting factors).
• aPTT: Prolonged (corrects with Factor VIII/IX concentrates).
• PT: Normal.
• Factor assay: Confirms specific factor deficiency and severity.

PRIORITY NURSING DIAGNOSIS:

• Risk for injury/bleeding (related to clotting factor deficiency).
• Acute pain (related to hemarthrosis or other bleeds).
• Chronic pain and limitation of mobility (related to joint damage from recurrent bleeds).
• Knowledge deficit (related to living with hemophilia and preventing complications).

Critical Nursing Interventions:

1. Acute Joint Bleed Management (RICE Protocol):

When hemarthrosis occurs, the priority is to stop bleeding, reduce pain, and prevent joint damage:

• Rest: Immobilise the affected joint immediately.
• Ice: Apply ice (wrapped in cloth to avoid direct skin contact) for 15 minutes, several times daily for the first 24–48 hours to vasoconstrict and limit bleeding.
• Compression: Use compression garments or elastic bandages to reduce swelling (though extreme compression can worsen ischemia).
• Elevation: Elevate the joint above heart level to reduce blood flow.
• Factor replacement: This is the cornerstone. Give Factor VIII or IX concentrates (dose depends on baseline factor level and severity of bleed) to stop active bleeding. The goal is to raise factor activity to ≥30% acutely. Some products are derived from donated plasma (plasma-derived) or recombinantly produced (recombinant); both are effective.
• Analgesics: Acetaminophen is safe; NSAIDs and aspirin are contraindicated (impair platelet function and worsen bleeding).
• Physical therapy: Once acute pain subsides, gentle range-of-motion exercises prevent joint stiffness and maintain function.

2. Prevention of Bleeding:

• Avoid trauma: Encourage a normal life with non-contact sports (swimming, cycling, golf) and discourage contact/collision sports (football, hockey, boxing).
• Dental care: Use a soft toothbrush and regular dental cleanings. Inform dentists of hemophilia so they can use local anesthetics with epinephrine and avoid traumatic extractions.
• Medication safety: AVOID aspirin and NSAIDs (impair platelet function). Use acetaminophen for pain and fever. List hemophilia on all medication records.
• No IM injections: Use IV or subcutaneous (SC) routes; even SC injections require careful technique and factor coverage.
• Safe environment at home: Remove trip hazards, use soft furnishings, pad sharp corners (especially in younger children).
• Protective gear: Helmets for biking, wrist/knee pads for skating.
• Medical alert identification: Teach the child to wear a medical-alert bracelet or necklace (e.g., "Factor VIII deficiency") to ensure prompt, correct treatment if injured or unconscious.

3. Factor Replacement Therapy:

• On-demand therapy: Given when bleeding occurs or is imminent (e.g., after trauma or before dental work). Doses are calculated based on baseline factor level and target level.
• Prophylactic therapy: Scheduled infusions (2–3 times weekly for Hemophilia A; 1–2 times weekly for Hemophilia B) to maintain factor levels and prevent spontaneous bleeds. Prophylaxis dramatically reduces joint damage and improves quality of life but requires venous access (central line) and adherence.
• DDAVP (desmopressin): An antidiuretic hormone analogue that raises Factor VIII levels in mild-to-moderate Hemophilia A (not helpful in Hemophilia B). Given as an IV infusion or intranasal spray; useful before dental procedures or minor surgery.
• Storage: Teach families to store concentrates per manufacturer instructions (often refrigerated); ensure they understand thawing protocols and have a plan for emergencies.

4. Family Education:

• Teach parents and the child (age-appropriate) to recognise early signs of bleeding (joint warmth/swelling, muscle tightness, abdominal pain) and seek treatment promptly.
• Explain the inheritance pattern and discuss genetic counselling options; daughters of affected males should know they are carriers.
• Provide written guides and resources from hemophilia organisations (e.g., World Federation of Hemophilia); many countries, including the Philippines, have support networks.
• Discuss psychosocial impact: children with hemophilia may experience anxiety, overprotection, or peer isolation. Encourage normal development and age-appropriate independence.
• Emphasise the importance of staying up to date on immunisations (including hepatitis A and B, given the historical risk of blood-borne infections from transfusions).

Sickle cell disease is an inherited blood disorder caused by a genetic mutation resulting in abnormal hemoglobin S (HbS). The abnormal haemoglobin polymerises and distorts red blood cells into a characteristic sickle (crescent) shape under conditions of low oxygen, dehydration, infection, cold, or acidosis. This leads to vaso-occlusion (vessel blockage) causing acute pain and chronic organ damage. Sickle cell disease is autosomal recessive, meaning a person must inherit the gene from both parents. Those with one sickle gene (heterozygous) have sickle cell trait, which is usually asymptomatic but may cause symptoms under extreme stress (e.g., high altitude, intense exertion).

Epidemiology:

Sickle cell disease is most common in people of African descent (1 in 365 African Americans in the USA; higher prevalence in sub-Saharan Africa, the Mediterranean, and the Middle East). In the Philippine context, sickle cell disease is less common than in some other populations, but it does occur and must be recognised and managed appropriately.

Pathophysiology:

The point mutation in the β-globin gene results in glutamic acid being replaced by valine at position 6, producing HbS. Under hypoxic conditions, HbS molecules polymerise into long fibres, distorting the RBC into a sickle shape. Sickled RBCs are rigid and adhere to endothelium, causing vaso-occlusion. They are also more fragile and haemolyse prematurely, leading to chronic haemolytic anemia. The spleen becomes damaged and congested from sickling, eventually becoming functionally asplenic ("autoinfarction") by childhood, increasing infection risk from encapsulated organisms (Streptococcus pneumoniae, Haemophilus influenzae, Salmonella).

Crises: Types and Triggers

Children with sickle cell disease experience unpredictable crises. Understanding crisis types and triggers is essential for NLE:

1. Vaso-Occlusive (Painful) Crisis:
The most common crisis, occurring when sickled cells occlude small vessels, causing acute ischemic pain. Often triggered by:

• Hypoxia (high altitude, flying, asthma exacerbation, pneumonia, anaesthesia).
• Dehydration (inadequate fluid intake, diarrhoea, vomiting, diuretics).
• Infection (fever-induced sickling).
• Cold exposure (cold weather, ice cream, cold showers).
• Acidosis (hyperventilation, respiratory/metabolic acidosis).
• Stress (emotional, surgical).
• Strenuous exertion (intense exercise).

Presentation: Sudden onset of severe pain in extremities (hands/feet), abdomen, back, or chest. Children may cry, hold affected limbs, and have fever. Hand/foot swelling in infants is called dactylitis or "hand-foot syndrome." Older children may have abdominal pain, chest pain (acute chest syndrome), or priapism (sustained erection with sickled cells in the corpora cavernosa).

2. Acute Splenic Sequestration Crisis:
Sickled cells pool in the spleen, causing acute splenic enlargement, severe anemia, hypovolemic shock, and potentially death if untreated. More common in children <5 years before the spleen becomes fibrosed. Presents with rapid onset of severe abdominal pain, massive splenomegaly, anaemia, and hypotension.

3. Aplastic Crisis:
A sudden cessation of RBC production (often triggered by parvovirus B19 infection) causing severe anemia and reticulocytopenia (low reticulocyte count, unlike the usual reticulocytosis of sickle cell). Presents with pallor, fatigue, dyspnea, and a very low hemoglobin.

4. Acute Chest Syndrome:
A life-threatening condition characterised by fever, chest pain, cough, dyspnea, and new infiltrates on chest X-ray. Caused by fat embolism (from bone marrow infarction), infection, or pulmonary infarction. Can rapidly progress to respiratory failure and death.

PRIORITY NURSING DIAGNOSIS:

• Acute pain (related to vaso-occlusion).
• Risk for tissue perfusion/organ damage (related to vaso-occlusion).
• Risk for infection (related to functional asplenia).
• Deficient fluid volume (related to chronic hemolysis and crisis).
• Chronic anaemia.

Critical Nursing Interventions: HHOP Management

The cornerstone of acute crisis management is summarised by the HHOP mnemonic:

H = Hydration: Aggressively rehydrate the child (orally if able, IV if not) to dilute the blood and promote sickling reversal. IV fluids (normal saline or hypotonic saline—never hypotonic dextrose which worsens sickling) are titrated based on hydration status, urine output, and vital signs. Maintain urine output ≥1 mL/kg/hour.

H = Heat (Warmth): Apply warmth to affected areas; NEVER apply cold (cold promotes further sickling). Warm compresses or blankets increase vasodilation and comfort.

O = Oxygen: Supplement oxygen to maintain SpO₂ ≥92–94% and prevent hypoxia. In acute chest syndrome, aggressive oxygen therapy is critical. However, avoid hyperoxia (>100% O₂) which can suppress erythropoiesis and worsen anaemia.

P = Pain Control: Administer opioids (morphine, hydromorphone, fentanyl) aggressively for severe pain. Titrate doses to effect; do not undertreat pain in sickle cell crises. Multimodal analgesia (opioids + NSAIDs, though NSAIDs are avoided if renal disease is present, and + non-pharmacological approaches) is effective. Patient-controlled analgesia (PCA) gives the child autonomy and ensures timely pain relief.

Additional acute crisis measures:

• Assess and treat infection: Obtain blood cultures, chest X-ray (to rule out pneumonia or acute chest syndrome), and urinalysis. Start broad-spectrum antibiotics if infection is suspected.
• Rest and immobilisation: Keep the child comfortable and at rest.
• Exchange transfusion: In severe acute chest syndrome or splenic sequestration, exchange transfusion (replacing sickled RBCs with normal RBCs from donors) may be life-saving. The goal is to dilute HbS to <30% of total hemoglobin.
• Monitor vital signs, urine output, and organ function: Track signs of organ damage (creatinine for kidney, troponin/BNP for heart).

Chronic Management and Prevention:

1. Hydroxyurea (HU):
A disease-modifying agent that increases fetal hemoglobin (HbF), which does not polymerise. HU reduces the frequency and severity of crises by up to 50%, improves survival, and reduces organ damage. Requires:

• Regular CBC monitoring (watch for myelosuppression).
• Adequate hydration and nutrition.
• Baseline and periodic assessment of renal and hepatic function.
• Pregnancy planning (HU is teratogenic).

2. Avoid Crisis Triggers:

• Maintain excellent hydration (encourage fluid intake, use electrolyte solutions in hot climates).
• AVOID high altitude (planes at altitude have lower cabin pressure; many experts recommend supplemental O₂ for sickle cell patients on long flights).
• AVOID strenuous exertion (but encourage regular age-appropriate activity).
• AVOID extreme cold exposure; dress warmly in winter.
• AVOID overheating and dehydration in hot climates.
• Treat infections promptly; maintain up-to-date immunisations (including pneumococcal, meningococcal, H. influenzae type b vaccines; annual influenza vaccine).
• Manage asthma and respiratory conditions to prevent hypoxia.

3. Family Education and Psychosocial Support:

• Teach families to recognise early warning signs of crisis (sudden pain, fever, rapid breathing, chest pain) and seek emergency care immediately.
• Explain the inheritance pattern and offer genetic counselling; siblings should be screened.
• Discuss the psychological impact of a chronic, unpredictable disease. Children may experience school absences, limitations on activities, and psychosocial stress. Coordinate with school counsellors and mental health providers.
• Provide written crisis management plans for school, daycare, and other settings.
• Connect families to sickle cell support organisations and care coordination services.

Thalassemia is an autosomal recessive inherited disorder characterised by defective synthesis of one of the globin chains of hemoglobin. This results in severe microcytic, hypochromic anemia, chronic hemolysis, and iron overload from repeated transfusions. There are two main types: alpha (α)-thalassemia (defective α-globin chains) and beta (β)-thalassemia (defective β-globin chains). For NLE purposes, the focus is on β-thalassemia major (Cooley's anemia), the most severe form, which presents in infancy/early childhood and requires lifelong transfusions.

Pathophysiology:

In β-thalassemia major, there is little or no synthesis of β-globin chains. Since each hemoglobin molecule contains two α-chains and two β-chains, excess α-chains accumulate and precipitate, damaging the RBC membrane and leading to premature haemolysis. The bone marrow attempts to compensate with massively increased erythropoiesis, leading to:

1. Severe microcytic, hypochromic anemia from decreased hemoglobin and dysfunctional RBCs.
2. Profound extramedullary hematopoiesis: The liver and spleen enlarge dramatically as they attempt blood cell production. This leads to massive hepatosplenomegaly (liver and spleen may enlarge 2–3 times normal size).
3. Bone marrow expansion: Hyperactive bone marrow expands within the skull and facial bones, causing characteristic facial features: frontal bossing (prominence of the forehead), maxillary prominence (protruding upper jaw), and often dental malocclusion.
4. Chronic hemolysis: RBCs are destroyed rapidly; chronic hyperbilirubinemia can lead to jaundice and gallstones.

5. Iron overload (hemosiderosis/hemochromatosis): Each unit of transfused blood contains ~250 mg of iron. Because humans have no physiologic mechanism to excrete excess iron, iron accumulates in the heart, liver, pancreas, pituitary, and other organs, causing:

   • Cardiac disease: Dilated cardiomyopathy, arrhythmias (leading cause of death in thalassemia major).
   • Cirrhosis and hepatic failure.
   • Endocrine dysfunction: Diabetes mellitus, hypogonadism, hypothyroidism, growth hormone deficiency.

Clinical Presentation:

Infants typically present between 3–6 months of age with:

• Severe anemia (hemoglobin often <5 g/dL) causing pallor, tachycardia, and dyspnea.
• Failure to thrive and feeding difficulties.
• Hepatosplenomegaly (markedly enlarged).
• Jaundice from chronic hemolysis.
• Characteristic facies: frontal bossing, maxillary prominence.

Diagnosis:

• CBC: Severe microcytic, hypochromic anemia (MCV <70 fL, MCH <20 pg), high RBC count (paradoxically, due to immature RBC release), reticulocytosis.
• Hemoglobin electrophoresis: Shows predominantly HbF (fetal hemoglobin) and HbA2, with absent or very low HbA (adult hemoglobin). This is the gold standard for diagnosis.
• Peripheral blood smear: Target cells (Mexican hat appearance), nucleated RBCs, anisocy­to­sis, poikilocytosis.

PRIORITY NURSING DIAGNOSIS:

• Chronic anaemia (related to ineffective erythropoiesis and hemolysis).
• Risk for organ damage (related to iron overload from chronic transfusions).
• Risk for infection (related to splenectomy in some cases and immunosuppression from frequent transfusions).
• Imbalanced nutrition less than body requirements (related to growth failure and chronic illness).

Critical Nursing Interventions:

1. Chronic Transfusion Management:

Children with β-thalassemia major require regular blood transfusions (often monthly or more frequently) to maintain hemoglobin ≥9–10 g/dL, ensuring adequate oxygen delivery and suppressing ineffective erythropoiesis. Nursing responsibilities include:

• Transfusion monitoring: Check vital signs before, during, and after transfusion. Watch for signs of transfusion reaction (fever, chills, rash, dyspnea, chest pain, haemoglobinuria). Stop the transfusion immediately if reaction occurs, keep the IV open with normal saline, notify the physician, and obtain post-transfusion labs.

• Prevent transfusion-related complications:

  • Alloimmunisation: Repeated exposure to foreign RBC antigens can lead to RBC antibody formation, making future crossmatching and transfusion difficult. Use leucodepleted blood (removes WBCs that carry HLA and other antigens) to reduce alloimmunisation risk.
  • Volume overload: Transfusions can cause hypervolemia, especially in children with cardiac compromise. Monitor for signs of heart failure (tachycardia, gallop rhythm, pulmonary crackles, hepatomegaly, edema). Consider diuretics if needed.
  • Transfusion-transmitted infections: Although screening is rigorous, residual risk of hepatitis C, HIV, and other bloodborne pathogens exists. Counsel on vaccination (hepatitis A and B) and regular serologic monitoring.
• Venous access: Repeated transfusions over years require reliable venous access. A central venous catheter (e.g., Hickman line, port-a-cath) may be placed to reduce peripheral vein damage and allow easier access for transfusions and blood draws.

2. Iron Chelation Therapy: The Critical Priority

Iron overload is perhaps the greatest long-term threat in thalassemia major. Chelation therapy (iron-binding treatment) removes excess iron and is essential for survival:

Deferoxamine (DFO):

• A parenteral iron chelator, historically the gold standard.
• Administered subcutaneously (SC) or intravenously (IV), usually 5–6 nights per week, at a dose of ~20–30 mg/kg/night.
• Binds iron and promotes urinary/fecal excretion.
• Adverse effects: Hearing loss (ototoxicity), visual problems (retinal damage), growth retardation, local reactions at infusion sites, hypersensitivity reactions.
• Monitoring: Baseline and annual audiometry and ophthalmologic exams; serum ferritin levels monthly (goal <2,500 ng/mL) and iron studies.
• Challenge: The need for frequent SC/IV infusions (often nightly) is burdensome for children and families, affecting adherence. Portable infusion pumps can improve compliance.

Deferasirox (DFX):

• An oral iron chelator (a game-changer for adherence).
• Dose: ~20–30 mg/kg once daily, adjusted based on ferritin levels.
• Chelates iron through GI excretion.
• Advantages: Oral route, once-daily dosing, improved adherence, reduced hospitalisation.
• Adverse effects: GI upset, abdominal pain (take on empty stomach; split doses may reduce GI symptoms), rash, hepatotoxicity, renal dysfunction. Less ototoxicity and ophthalmotoxicity than DFO.
• Monitoring: Monthly serum ferritin, baseline and periodic liver (AST/ALT) and renal function (serum creatinine, urinalysis); annual audiology and eye exams.

Deferiprone (DFP):

• Another oral option; used mainly when DFO/DFX are contraindicated or ineffective.
• Dose: ~25 mg/kg three times daily.
• Adverse effect: Risk of agranulocytosis (dangerous drop in WBC); requires regular CBC monitoring.

Combined chelation: Sometimes two agents are used together for synergistic effect (e.g., DFO + DFX).

Monitoring for iron overload complications:

• Cardiac: Baseline and periodic electrocardiography (ECG) and echocardiography; troponin/BNP for cardiomyopathy. Arrhythmias and dilated cardiomyopathy signal severe iron overload.
• Hepatic: Liver iron content measured by magnetic resonance imaging (MRI); liver function tests; ultrasound to assess for cirrhosis.
• Endocrine: Fasting glucose (diabetes screening), thyroid function (TSH, free T4), gonadal hormones (LH/FSH, testosterone/estrogen for puberty assessment).

3. Growth and Development:

Children with thalassemia often have growth retardation due to chronic anaemia, iron overload effects on the pituitary (growth hormone deficiency), and nutritional deficiencies. Nursing measures:

• Monitor height and weight: Plot on thalassemia-specific growth charts (not standard charts, which underestimate the severity of growth failure).
• Nutrition: Assess dietary intake; provide nutritional counselling and supplements if needed. Iron fortification of foods may be limited due to iron overload.
• Growth hormone therapy: If growth hormone deficiency is documented, hormone replacement may improve growth.

4. Splenectomy:

Some children develop splenomegaly so severe that it compromises breathing and is a transfusion sink (consumes transfused RBCs rapidly, increasing transfusion frequency). Splenectomy may be performed after age 5–6 years (to allow immune system maturation) if the spleen is massive. Post-splenectomy, the child must receive:

• Prophylactic penicillin V (long-term or indefinitely) to prevent overwhelming post-splenectomy infection (OPSI) from encapsulated organisms (Streptococcus pneumoniae, Haemophilus influenzae).
• Pneumococcal, meningococcal, and H. influenzae type b vaccines before splenectomy if possible.
• Education about signs of infection and need for immediate antibiotic treatment.

5. Psychosocial Support:

Thalassemia major is a demanding, lifelong illness. Regular transfusions, frequent clinic visits, chelation therapy burdens, and the knowledge that complications may develop despite adherence create significant psychological strain. The nurse:

• Validates the child and family's feelings.
• Coordinates with psychologists, social workers, and support groups.
• Helps families problem-solve adherence challenges (e.g., making chelation more convenient, finding compatible chelation regimens).
• Celebrates milestones and normalcy wherever possible.

Iron-deficiency anemia (IDA) is the most prevalent nutritional deficiency and the most common cause of anemia in children worldwide, particularly in low-income and middle-income countries including many regions of the Philippines. It occurs in two peak periods: infants and toddlers (6 months – 3 years) and adolescents, especially menstruating females. Unlike genetic or malignant causes of anemia, IDA is largely preventable through proper nutrition and iron supplementation.

Pathophysiology:

Iron is essential for hemoglobin synthesis (each hemoglobin molecule contains an iron-containing heme group). Without adequate iron, the bone marrow cannot produce sufficient hemoglobin, resulting in microcytic (small), hypochromic (pale) red blood cells. Causes of IDA in children include:

1. Inadequate dietary iron intake (the most common cause in developing countries):

   • Delayed introduction of iron-rich complementary foods after 6 months of exclusive breastfeeding.
   • Excessive cow's milk intake in toddlers ("milk baby" syndrome): cow's milk is low in iron and ironically, high milk intake displaces iron-rich foods from the diet. Additionally, cow's milk protein can cause microscopic GI bleeding, further lowering iron stores.
   • Breastfeeding beyond 6 months without iron supplementation or iron-rich foods (breast milk is low in iron and does not meet infant needs beyond 6 months).
   • Plant-based or vegetarian diets without adequate iron-rich legumes.

2. Blood loss:

   • GI bleeding (cow's milk protein enterocolitis, hook­worm infection in endemic areas, inflammatory bowel disease).
   • Heavy menstrual bleeding in adolescent females (menorrhagia).
   • Hemorrhage from trauma or surgery.

3. Malabsorption:

   • Celiac disease, cystic fibrosis, Crohn's disease.
   • Conditions affecting the duodenum (site of iron absorption).

4. Increased iron demand:

   • Rapid growth in infancy and childhood.
   • Pregnancy and lactation (in adolescent mothers).

Clinical Presentation:

Mild-to-moderate IDA often has few symptoms (especially in infants/toddlers). Signs include:

• Pallor (pale skin, conjunctivae, palms).
• Fatigue and decreased activity (infants may be irritable or have poor feeding).
• Tachycardia and tachypnea (compensatory).
• Poor appetite (pica: craving non-food items like dirt, ice, starch—common in developing countries and suggests severe deficiency).
• Developmental delay (chronic iron deficiency in infancy affects cognitive development, motor skills, and behaviour).
• Glossitis and angular cheilitis (in severe deficiency).
• Splenomegaly (mild, if chronic).

Laboratory Findings:

• CBC: Hemoglobin typically 7–11 g/dL (varies with severity); microcytic (MCV <70 fL), hypochromic (MCH <20 pg) RBCs; normal to elevated RBC count (reticulocytosis if blood loss is acute); normal WBC and platelet count.

• Iron studies:

  • Serum ferritin: <12 ng/mL (depleted iron stores). This is the most sensitive and specific marker for IDA.
  • Serum iron: Low (<50 µg/dL).
  • Total iron-binding capacity (TIBC): Elevated (>400 µg/dL).
  • Transferrin saturation: <16%.
  • Soluble transferrin receptor: Elevated (useful when ferritin is elevated due to inflammation, which can mask iron deficiency).
• Peripheral blood smear: Microcytic, hypochromic cells; possible target cells; anisocytosis (variation in RBC size).

PRIORITY NURSING DIAGNOSIS:

• Imbalanced nutrition less than body requirements (related to inadequate iron intake or malabsorption).
• Ineffective tissue perfusion (related to reduced oxygen-carrying capacity from anaemia).
• Activity intolerance (related to anaemia).
• Delayed growth and development (related to chronic iron deficiency in infancy).
• Knowledge deficit (related to iron supplementation and dietary iron sources).

Critical Nursing Interventions:

1. Iron Supplementation: Oral Iron Therapy

Oral iron is the first-line treatment for IDA. The typical dose is 3–6 mg/kg/day of elemental iron, usually divided into two daily doses. Common formulations include:

• Ferrous sulfate (FeSO₄): The most common, least expensive, and best-absorbed form. A 325-mg ferrous sulfate tablet contains ~65 mg of elemental iron.
• Ferrous fumarate: Slightly better absorbed; less GI upset than ferrous sulfate.
• Ferrous gluconate: Milder GI effects but less iron content per dose.

Administration and Family Teaching:

Teaching families the correct administration of iron is crucial for treatment success. The nurse should provide clear, written instructions:

• On an empty stomach (1 hour before or 2 hours after meals) for best absorption: Iron absorption is enhanced in acidic conditions. Food, especially phosphates (in dairy, eggs) and tannins (in tea, coffee), impair absorption. However, if GI upset occurs, iron can be given with food (though absorption drops by 20–40%).
• WITH vitamin C (citrus juice—orange, grapefruit, or lemon juice): Vitamin C (ascorbic acid) is a powerful iron absorption enhancer, converting ferric iron to ferrous form. Give iron supplement with 4–6 ounces of citrus juice (not apple or grape juice). This can reduce needed dose and improve efficacy.
• NOT with milk or dairy: Calcium, phosphate, and casein in milk inhibit iron absorption; separate iron from dairy by at least 2 hours.
• NOT with tea, coffee, or cola: Tannins and phosphates inhibit absorption.
• Administer using a straw or dropper toward the back of the mouth (liquid iron permanently stains teeth black/brown—this is a very common side effect that distresses families if not warned beforehand).
• Brush teeth after administration to minimize staining.
• Expect dark, tarry (black) stools: This is normal and indicates iron is being absorbed. If stools are not dark, absorption may be poor; review adherence and timing with meals.
• Possible constipation: Iron supplements commonly cause constipation, especially in young children. Recommend increased fibre, fluids, and physical activity; a stool softener or mild laxative may be needed.
• Possible nausea, abdominal discomfort, or cramps: Start with a low dose and gradually increase to tolerance. If GI upset is severe, discuss with the provider about reducing dose, giving with food (at some absorption cost), or switching iron formulations.
• Duration of therapy: Iron supplementation typically continues for 3–6 months after hemoglobin normalises to replete iron stores (ferritin >12 ng/mL). Do not stop prematurely; relapse is common.

CRITICAL SAFETY WARNING: Iron Poisoning in Young Children

Accidental iron overdose is one of the leading causes of poisoning death in young children in many regions. Liquid iron supplements and iron tablets are very palatable to children. Implement:

• Keep all iron supplements locked away, out of reach of young children. This is non-negotiable.
• Educate parents on toxicity signs: nausea, vomiting, abdominal pain, dark/bloody stools, lethargy, shock. If ingestion is suspected, contact poison control or go to ED immediately.
• Do not leave iron bottles on bedside tables, in purses, or anywhere accessible.

2. Dietary Counselling: Non-Supplemental Iron

For infants/toddlers and for long-term prevention, dietary iron is equally important:

• Breastfed infants (6–12 months): Introduce iron-fortified infant cereal at 6 months; add iron-rich complementary foods (meat, poultry, fish, eggs, legumes). Continue breastfeeding (ideally to 24 months) alongside foods.
• Formula-fed infants: Use iron-fortified infant formula from birth to 12 months.

• Toddlers (1–3 years): Limit cow's milk to 16–24 ounces daily; use iron-fortified milk if available (though this is less common). Emphasise iron-rich foods:

  • Heme iron (better absorbed, especially from animal sources): Red meat (beef, liver), poultry, fish, shellfish.
  • Non-heme iron (plant sources, lower bioavailability): Legumes (beans, lentils, peanuts), leafy greens (spinach, amaranth), fortified cereals, nuts, seeds.
  • Pair iron with vitamin C sources: Orange juice, tomatoes, bell peppers, mango enhance iron absorption from any source.
• Adolescents: Emphasise iron-rich foods; screen menstruating females for heavy periods (which may require iron supplementation beyond dietary sources).

Prevention in the Philippine Context:

The Philippine Department of Health has implemented several initiatives to combat IDA:

• Rice fortification: Iron-fortified rice is mandated in many schools and public programmes.
• Micronutrient supplementation programmes: National iron supplementation programmes target pregnant women, postpartum mothers, and young children. School-based deworming and iron supplementation are common (deworming reduces GI blood loss).
• Health education: Community nurses and health workers provide nutrition counselling emphasising iron-rich foods, reduction of excessive milk intake, and iron supplementation adherence.

3. Assessment of Response to Iron Therapy

• Clinical response: Within 2–3 weeks, the child should show improved activity, appetite, and alertness.
• Reticulocyte count: Increases within 3–5 days (indicates bone marrow response); peaks at ~10–14 days.
• Hemoglobin: Rises by ~1 g/dL every 1–2 weeks; normalisation usually achieved by 6–8 weeks.
• Iron studies: Ferritin, serum iron, and TIBC normalise over weeks to months.
• If no response: Reassess adherence, absorption (consider malabsorption), continued blood loss, or misdiagnosis.

4. Management of Underlying Causes

Address the root cause:

• If due to excessive milk intake: Educate parents on limiting cow's milk and increasing iron-rich foods.
• If due to blood loss (e.g., GI bleed, menorrhagia): Investigate and treat the cause.
• If due to malabsorption: Treat the underlying condition (e.g., celiac disease, hookworm).

Immune thrombocytopenic purpura (ITP), formerly called idiopathic thrombocytopenic purpura, is an acquired autoimmune disorder in which the immune system attacks and destroys platelets, leading to isolated thrombocytopenia (very low platelet count) with normal hemoglobin and WBC. This distinguishes it from leukaemia or other bone marrow disorders, where multiple cell lines are reduced. ITP in children is often acute (sudden onset, self-limited) and distinct from chronic ITP in adults.

Pathophysiology:

In ITP, autoimmune IgG antibodies target the glycoprotein IIb/IIIa complex on the platelet surface. The spleen and reticuloendothelial system recognise these antibody-coated platelets as foreign and destroy them via antibody-dependent cell-mediated cytotoxicity (ADCC). The bone marrow responds with increased thrombopoiesis (platelet production), but production cannot keep up with destruction, resulting in thrombocytopenia (platelet count <150,000/μL; severe if <20,000/μL).

Triggering Events:

Acute ITP often follows a viral infection (measles, mumps, rubella, varicella, CMV, EBV, parvovirus B19) by 2–4 weeks or a vaccination (especially MMR or varicella vaccine). The viral infection is thought to trigger molecular mimicry—immune cross-reactivity between viral antigens and platelet antigens.

Clinical Presentation:

A child with acute ITP typically presents suddenly with widespread bruising and petechiae (pinpoint red/purple spots that don't blanch) after a recent viral illness. The child otherwise looks well—a key distinguishing feature from leukemia (where the child is often acutely ill with fever and organomegaly). Signs and symptoms include:

• Petechiae and purpura: Often first noticed on the lower extremities and buttocks (areas of higher capillary pressure); may coalesce into large bruises.
• Bleeding from mucous membranes: Nosebleeds (epistaxis), gum bleeding, blood-stained saliva.
• Rarely, severe bleeding: Intracranial hemorrhage (ICH) is the most feared complication but is rare (<1% of children with ITP); GI bleeding, retinal hemorrhage.
• Splenomegaly: Mild; the spleen destroys platelets but rarely becomes massive (unlike in leukaemia).
• Otherwise well-appearing: The child is playful, afebrile, with normal WBC and hemoglobin—this contrasts sharply with leukemia.

Diagnosis:

• CBC: Isolated thrombocytopenia (very low platelets, often <20,000/μL; sometimes <1,000/μL); hemoglobin and WBC are normal. The RBC smear should show normal cells, distinguishing it from other conditions.
• Bleeding time: Normal (tests platelet function, which is intact).
• PT/aPTT: Normal (clotting factors are normal).
• Platelet-associated IgG (PAIgG): Elevated (confirms immune attack), though not routinely measured.
• Peripheral blood smear: Absence of abnormal cells; adequate megakaryocytes on bone marrow biopsy (if performed, showing the marrow is responding appropriately to produce platelets).

Differential diagnosis is crucial: ITP must be distinguished from:

• Leukemia: A CBC showing WBC >50,000 or <1,000, anaemia, low hemoglobin, or abnormal cells rules out simple ITP.
• Drug reaction: Certain drugs (antibiotics, NSAIDs, trimethoprim) can cause thrombocytopenia; obtain a medication history.
• Other causes: Systemic lupus erythematosus (SLE), antiphospholipid syndrome, HIV, hepatitis C, infections.

PRIORITY NURSING DIAGNOSIS:

• Risk for injury/bleeding (related to severe thrombocytopenia).
• Acute pain (from bruising, if applicable).
• Anxiety (the child and family may be frightened by the sudden appearance of bruising).

Critical Nursing Interventions:

1. Bleeding Precautions

Once ITP is diagnosed, implement strict bleeding precautions, regardless of whether the child is on treatment:

• Soft toothbrush: Use a soft-bristled toothbrush; avoid vigorous brushing and flossing.
• Avoid contact sports and high-risk activities: No football, hockey, wrestling, trampolines, or activities with high fall risk. Swimming, cycling, and other non-contact activities are fine.
• NO aspirin or NSAIDs: These impair platelet function and worsen bleeding. Recommend acetaminophen for pain/fever.
• Avoid IM injections: All medications should be given IV or orally. If SC injection is necessary (e.g., allergy emergency), use careful technique and apply pressure.
• Avoid trauma: Educate the family on environmental safety (no rough play, soft furnishings, safety gates for toddlers).
• Medical alert identification: Recommend a medical-alert bracelet stating the platelet count.
• Avoid rectal thermometers, suppositories, and rectal examinations.
• Educate on signs of serious bleeding: Severe headache, vomiting, altered consciousness (ICH), abdominal pain (GI bleed), bloody urine (genitourinary bleed), black tarry stools (GI bleed)—seek emergency care immediately if these occur.

2. Assessment and Monitoring

• Serial platelet counts: Monitor trend. In acute ITP, platelets may rise spontaneously even without treatment within 4–6 weeks.
• Signs of ICH: Headache, seizures, altered consciousness, focal neurologic deficits. Any concerning neurologic symptom warrants urgent CT/MRI.
• Vital signs and weight: Baseline assessment; monitor for signs of bleeding.

3. Treatment Considerations

Management of ITP depends on platelet count, bleeding symptoms, and the clinical course:

Observation/Watchful waiting:
Many children with acute ITP (60–80%) recover spontaneously within 3–6 months. If the platelet count is >30,000/μL and there is no significant bleeding, some experts recommend observation without treatment, allowing the immune system to self-resolve. Regular counts and bleeding precautions are maintained.

Corticosteroids:
First-line pharmacologic treatment if bleeding is significant or platelet count is very low. Prednisolone or dexamethasone suppresses the immune attack on platelets. Typical dose: prednisolone 1–2 mg/kg/day (or dexamethasone 0.6 mg/kg/day as a single dose for 4 days, then taper). Most children respond within 3–5 days with platelet count rising. Administer with a proton pump inhibitor (omeprazole) to protect the stomach. Monitor for side effects (insomnia, mood changes, increased appetite, hyperglycemia). Most children can taper steroids over 2–4 weeks without relapse.

IVIG (intravenous immunoglobulin):
Used for rapid platelet increase in severely ill children (ICH risk, massive bleeding). IVIG has pooled IgG antibodies from many donors; the mechanism is thought to be blockade of Fc receptors on splenic macrophages, preventing platelet destruction. Dose: 0.8–1.0 g/kg IV infusion. Platelet response is rapid (24–48 hours) but transient (days to weeks). Given when urgent platelet elevation is needed (e.g., before surgery or with life-threatening bleeding).

Anti-D immunoglobulin (in Rh-positive children):
Alternative to IVIG for rapid platelet increase in Rh-positive, non-splenectomised children. Coated RBCs are destroyed by the spleen preferentially over antibody-coated platelets, reducing platelet destruction. Dose-dependent response; similar timeline to IVIG.

Splenectomy:
Definitive treatment for chronic ITP (not acute). Removes the organ that destroys antibody-coated platelets. Usually deferred in acute ITP (most children recover spontaneously) but performed in children with chronic ITP not responding to steroids. Post-splenectomy, the child requires prophylactic penicillin and pneumococcal/meningococcal/H. influenzae type b vaccines to prevent OPSI.

4. Patient and Family Education

• Reassurance: Emphasise that ITP is usually self-limited in children; the sudden appearance of bruising is frightening, but the prognosis is generally excellent.
• Bleeding precautions: Provide written instructions on activity restrictions, medication safety (avoid aspirin/NSAIDs), and warning signs of serious bleeding.
• Expected course: Explain that platelet counts may fluctuate; some children relapse but many recover fully within months.
• Avoid unnecessary investigations: Once ITP is diagnosed, further bone marrow biopsies are usually not needed (marrow is responding appropriately with increased megakaryocytes).
• Support: Connect families to support resources; refer to psychology if the child is anxious about activity restrictions.

Down syndrome, caused by Trisomy 21 (three copies of chromosome 21 instead of the usual two), is the most common autosomal chromosome abnormality and the most common genetic cause of intellectual disability in children. Approximately 1 in 700 live births in developed countries are diagnosed with Down syndrome; the risk increases significantly with advanced maternal age (≥35 years). In the Philippine context, as in many developing countries, Down syndrome often goes undiagnosed or diagnosed late, underscoring the importance of awareness and early intervention.

Genetics and Risk Factors:

• Trisomy 21 (95% of cases): Full nondisjunction (meiotic error) resulting in complete extra chromosome 21. Risk rises dramatically with maternal age:

  • Age 20–24: 1 in 1,500 live births.
  • Age 30: 1 in 900.
  • Age 35: 1 in 350.
  • Age 40: 1 in 70.
  • Age 45: 1 in 30.
• Translocation Trisomy 21 (3–4% of cases): Part of chromosome 21 attaches to another chromosome (usually 14). Can be familial if a parent carries a balanced translocation; recurrence risk is higher (~10–15%) if the mother is a carrier.
• Mosaic Trisomy 21 (1–2% of cases): Some cells have two chromosome 21s, others have three. Phenotype is milder; intellectual disability and physical features are less severe.

Clinical Features:

Children with Down syndrome have characteristic physical and developmental features:

Facial Features:

• Upward-slanting palpebral fissures (inner corners of eyes higher than outer corners; this is the hallmark facial feature).
• Epicanthal folds: Skin folds on the inner aspect of the eyelids, often giving the false impression of "almond eyes" (though this is not specific to Down syndrome).
• Flat facial profile: Underdeveloped nasal bridge; the whole face appears flattened.
• Protruding tongue: Due to a small oral cavity; may cause feeding difficulties and sleep apnea.
• Short neck: Broad, may have excess skin folds ("buffalo hump" at the nape).

Extremities:

• Single transverse palmar crease (Simian crease): A single crease running across the palm; normally there are two creases. Present in ~45% of children with Down syndrome but not pathognomonic.
• Wide gap between first and second toes: Distinctive foot feature.
• Clinodactyly: Inward-curving fifth finger (pinky); may be shortened.

Musculoskeletal:

• Hypotonia (floppy infant): Marked decreased muscle tone at birth; infants appear "floppy" and weak. This gradually improves with age but persists to some degree.
• Short stature: Characteristic growth pattern; height falls below the standard growth curve. Use Down-syndrome-specific growth charts for accurate assessment.
• Laxity of ligaments: Joint hypermobility; risk of atlantoaxial instability (see below).

Developmental:

• Intellectual disability (variably severe): IQ typically 30–70 (moderate-to-mild range); some children have mild disability, others moderate-to-severe. Early intervention programmes significantly improve outcomes.
• Delayed motor milestones: Sitting, walking, and fine motor development are delayed (months to years behind). Hypotonia contributes.
• Speech delay: Often the most prominent developmental delay. Speech is delayed in onset and may be unclear (due to tongue size, oral cavity, and cognitive factors). Speech therapy is essential.

Associated Medical Conditions (CRITICAL FOR NLE):

Children with Down syndrome have a high incidence of associated medical problems that must be screened for and monitored:

1. Congenital Heart Defects (Very Common—up to 50% of children with Down syndrome):

• Atrioventricular (AV) canal defect (endocardial cushion defect): The most common cardiac lesion in Down syndrome (accounts for ~50% of cardiac defects in these children). Involves incomplete formation of the atrial and ventricular septa and abnormal AV valves. May be asymptomatic initially or cause signs of heart failure (tachypnea, poor feeding, failure to thrive, hepatomegaly, edema).
• Ventricular septal defect (VSD), atrial septal defect (ASD), tetralogy of Fallot: Also common.
• Nursing implications: Baseline ECG and echocardiography are essential for all infants with Down syndrome. Monitor for signs of heart failure; counsel on feeding (may require increased calories if cardiac work is high), activity limitations if needed, and the possibility of surgical repair. Prophylactic antibiotics for dental procedures (if the child has cardiac defects) are recommended to prevent endocarditis.

2. Gastrointestinal Anomalies:

• Duodenal atresia: Complete absence of the duodenum (proximal small bowel). Presents in the newborn period with bilious vomiting and abdominal distension. Diagnosed by abdominal X-ray showing the characteristic "double bubble" sign (air in the stomach and proximal duodenum, with no air distal to the obstruction). Requires surgical repair.
• Hirschsprung disease: Absence of ganglion cells (nerve cells) in the myenteric plexus of the bowel, preventing normal peristalsis. Presents as enterocolitis (severe diarrhea, abdominal distension, fever, shock) in the newborn period or as chronic constipation. Diagnosis by contrast enema ("transition zone") and rectal biopsy. Requires surgical resection of the aganglionic segment.
• Anal atresia/fistula, esophageal atresia, tracheoesophageal fistula: Less common but possible.
• Nursing implications: Monitor for signs of GI obstruction in newborns; feeding difficulties; constipation; coordinate with surgery as needed.

3. Atlantoaxial Instability:

• The atlantoaxial joint (between the first and second cervical vertebrae) may be hypoplastic or have ligamentous laxity due to hypotonia and connective tissue abnormality. This can lead to subluxation (partial dislocation) or instability, especially with neck flexion or trauma.
• Clinical significance: Increased risk of spinal cord compression with sudden neck movement. Caution is needed during neck flexion (e.g., during general anaesthesia intubation, some gymnastics moves, or contact sports).
• Screening: X-rays of the cervical spine (neutral, flexion, extension views) assess atlantoaxial distance. Most children do not require restriction from activities, but some may have sports restrictions (avoiding contact sports, gymnastics, diving) if instability is present.
• Nursing implications: Educate families on cautious neck handling (avoid excessive flexion); inform schools/coaches of possible restrictions; ensure healthcare providers (including anaesthesiologists) are aware of the instability before any procedure.

4. Hypothyroidism:

• Relatively common (~15–20% of children with Down syndrome). Autoimmune thyroiditis (Hashimoto's) or congenital hypothyroidism.
• Screening: TSH and free T4 at birth (via newborn screening—the Philippine Newborn Screening Program includes congenital hypothyroidism) and periodically thereafter (annually or as recommended).
• Treatment: Levothyroxine supplementation if TSH is elevated. Growth, development, and energy improve with adequate thyroid replacement.

5. Hearing Loss:

• Conductive hearing loss (due to recurrent otitis media, which is very common in Down syndrome) is more frequent than sensorineural hearing loss, but both occur.
• Screening: Newborn hearing screening (NBHS); age-appropriate audiometry. Most children have some degree of hearing loss.
• Intervention: Hearing aids, speech therapy, treatment of recurrent otitis media (may require tympanostomy tubes).

6. Vision Problems:

• Refractive errors (myopia, hyperopia, astigmatism), strabismus (eye misalignment), cataracts, nystagmus—common.
• Screening: Baseline and periodic ophthalmologic exams.
• Intervention: Glasses/contacts, surgery if needed (strabismus repair, cataract surgery).

7. Increased Risk of Infections:

• Immunological dysfunction (altered T and B cell function) increases susceptibility to infections, especially respiratory infections (otitis media, sinusitis, pneumonia) and GI infections.
• Management: Up-to-date immunisations (including annual flu, pneumococcal vaccines); prompt treatment of infections.

8. Increased Risk of Leukemia:

• Children with Down syndrome have a ~10–20 fold increased risk of leukemia (both ALL and AML). Acute megakaryoblastic leukemia (AMKL) has a particularly high association with Trisomy 21.
• Screening: Monitor for signs of leukemia (fever, bruising, pallor, hepatosplenomegaly); some recommend periodic CBC.

9. Sleep-Disordered Breathing:

• Obstructive sleep apnea (OSA) is common due to tonsillar/adenoidal hypertrophy and upper airway anatomy (narrow airway, glossoptosis from protruding tongue).
• Clinical signs: Snoring, witnessed apneas, restless sleep, morning headaches (in older children), daytime somnolence, behavioural problems.
• Screening: Sleep study (polysomnography) if OSA is suspected.
• Treatment: Adenotonsillectomy (may resolve OSA in many children), CPAP if surgery not effective or not feasible.

PRIORITY NURSING DIAGNOSIS (Using Maslow's Hierarchy):

• Physiological level: Risk for airway obstruction (OSA, hypotonia, large tongue), Impaired swallowing/feeding (related to hypotonia and oral/pharyngeal anatomy).
• Safety level: Risk for cardiac complications (undetected congenital heart disease), Risk for aspiration (feeding difficulties, reflux), Risk for atlantoaxial instability.
• Love and belonging: Parental coping and family adjustment.
• Self-actualisation: Delayed growth and development (related to hypotonia, intellectual disability, visual/hearing impairments); Feeding self-care deficit.

Critical Nursing Interventions:

1. Newborn Screening and Early Diagnosis:

• In the Philippines, Down syndrome is part of the expanded newborn screening programme. While cytogenetic testing (karyotype) and FISH (fluorescence in situ hybridisation) confirm diagnosis, the nurse's role includes:

  • Ensuring newborns are screened (ideally before discharge or within the first week of life).
  • Communicating results sensitively and supporting families through the initial crisis.
  • Referring to early intervention (Birth-to-Three programme or equivalent) immediately after diagnosis.

2. Feeding and Nutrition:

• Assess feeding ability: Hypotonia and the protruding tongue make sucking, swallowing, and feeding difficult. Infants may fatigue easily during feeds.
• Support feeding: Hold the infant's head firmly; feed slowly and patiently; allow extra time between swallows. Gavage feeding (via NG tube) may be necessary temporarily if the infant cannot meet nutritional needs orally.
• Monitor for aspiration: Watch for coughing/choking during feeds, signs of aspiration (fever, cough, crackles after feeds).
• Promote growth: Ensure adequate calories and nutrients; many children with Down syndrome have growth failure. Use Down-syndrome-specific growth charts for assessment. Consider high-calorie formula if oral intake is poor.
• Introduce solids: Begin at the age-appropriate time (~6 months) with soft, pureed foods if needed. Progress to thickened foods as the child develops. Be mindful of oral hypotonia (may require longer chewing time, risk of choking on hard/sticky foods).

3. Development and Early Intervention:

• Refer for early intervention immediately: Early intervention programmes (combining physical therapy, occupational therapy, speech therapy, and developmental education) initiated in infancy dramatically improve developmental outcomes. These programmes are mandatory in many developed countries and increasingly available in the Philippines through government and NGO initiatives.
• Physical therapy: Addresses hypotonia, promotes motor development (sitting, standing, walking). Therapy is ongoing; developmental progress is slower than typical children but is achievable.
• Occupational therapy: Addresses fine motor development and self-care skills (feeding, dressing, toileting).
• Speech therapy: Critical for addressing the speech delay; may use sign language or augmentative/alternative communication (AAC) devices if spoken speech is limited.
• Family education: Teach parents exercises and strategies to promote development at home; emphasise that every child's potential is unique and growth is possible throughout childhood and into adulthood.

4. Cardiac Assessment and Management:

• Baseline screening: All infants with Down syndrome should have an ECG and echocardiography within the first month of life to screen for congenital heart defects.
• Monitor for signs of heart failure: Tachypnea, poor feeding, failure to thrive, hepatomegaly, edema. If detected, refer to paediatric cardiology for evaluation and possible surgical repair.
• Endocarditis prophylaxis: If the child has a cardiac defect, prophylactic antibiotics before dental work may be recommended.
• Activity: Most children can be active; restrictions are individualised based on cardiac status.

5. Screening for Associated Conditions:

• Thyroid function: TSH and free T4 at birth (via newborn screening) and annually.
• Hearing: Newborn hearing screen and age-appropriate audiometry; early intervention for hearing loss (hearing aids, speech therapy).
• Vision: Baseline ophthalmology exam in infancy and periodically; glasses/contacts as needed.
• GI assessment: Monitor feeding, growth, and bowel patterns; screen for duodenal atresia in newborns (bilious vomiting, abdominal distension) and Hirschsprung disease (enterocolitis, chronic constipation).
• Atlantoaxial stability: X-ray of cervical spine (flexion/extension views) to assess for instability; counsel on activity restrictions if needed.
• Leukemia surveillance: Monitor for signs of leukemia; some experts recommend periodic CBC.

6. School and Community Integration:

• Inclusive education: Advocate for inclusion in regular schools with appropriate support (aide, modified curriculum, therapy services). Many children with Down syndrome can be educated in mainstream settings with adaptations.
• Social integration: Support opportunities for peer interaction, friendships, and community participation (sports, clubs, recreation).
• Transition planning: As the child approaches adulthood, plan for vocational training, day activities, and supported living options (varies by country and resources).

7. Family Support:

• Acknowledge the emotional impact: A Down syndrome diagnosis can be devastating for families initially. Provide compassionate, non-directive counselling.
• Connect to support: Refer families to Down syndrome support organisations (local and national), support groups, and family counselling services.
• Genetic counselling: Offer genetic counselling to parents to discuss recurrence risk and reproductive options for future pregnancies.
• Celebrate milestones: Reinforce that while development is delayed, many children with Down syndrome achieve independence in self-care, attend school, and develop relationships. Modern outcomes are remarkably positive with early intervention and adequate support.